Leukemia, Myelodysplasia, Transplantation

MD IQ

Conference Coverage

Acalabrutinib extends PFS in advanced CLL

AMSTERDAM – Monotherapy with the Bruton tyrosine kinase inhibitor acalabrutinib offered better progression-free survival, compared with rituximab-...

Pages